Compare Levi Strauss & Co. (LEVI) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Oscar Health Inc — how do they compare? Levi Strauss & Co. trades at $18.65 (market cap $7.31B), while Oscar Health Inc trades at $33.4 (market cap $10.22B). The key difference: Oscar Health Inc is the larger of the two by market cap, and Levi Strauss & Co. pays a 3.36% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 70 Days and Oscar Health Inc for 15 Days on average.
| LEVI | OSCR | |
|---|---|---|
Market Cap | $7.31B | $10.22B |
Volume | 13,683,095 | 4,123,394 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $33.81 |
52-Week Low | $17.92 | $10.85 |
Typical Hold Time | 70 Days | 15 Days |
Enterprise Value | $8.86B | $6.57B |
Dividend Yield | 3.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $18.70, down 4.15% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a P/E of 12.53 and consistent earnings beats, including Q3 2026 EPS of $0.48 versus $0.36 expected. Revenue for 2025 was $6.28 billion with a net income margin of 9.2%. Recent news highlights a new CFO appointment and positive analyst expectations for Q3 earnings.
The outlook is positive with a consensus price target of $29.00, implying 55% upside, supported by 78.95% analyst buy ratings. Risks include competitive pressures and recent cybersecurity incidents. The stock's valuation and earnings momentum present a compelling opportunity, though technical weakness warrants monitoring.
OSCR trades at $33.41, up 1.52% today, with a bullish technical signal and strong recent earnings beats in Q1 and Q2 2026. The stock shows robust revenue growth, with 2026 revenue projected at $15.3B and a return to profitability. Analyst sentiment is mixed but leans positive, with a consensus price target of $34.00. Recent news highlights market share gains and raised 2026 guidance, though the stock faces tests from rising medical costs.
The outlook is cautiously optimistic, driven by scalable growth in the ACA market and margin expansion opportunities. Key risks include medical cost pressures and competitive threats. Upside potential exists if the company executes on its 2029 EPS target of $4+, but investors should monitor profitability sustainability amid cost headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
